Overview

A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517. Two doses of Org 34517 will be compared to placebo in this international multicenter study. The duration of this trial is 6 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.